Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Systematic Meta-analysis
34%
Acute Myeloid Leukemia
33%
Overall Survival
31%
Venetoclax
30%
Meta-analysis
30%
Relapsed or Refractory
29%
Graft-versus-host Disease (GvHD)
28%
Chimeric Antigen Receptor T-cell Therapy
25%
Large B-cell Lymphoma
24%
Hematopoietic Cell Transplantation
20%
Multiple Myeloma
19%
Relative Risk
16%
Meta-analysis of Randomized Controlled Trials
15%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Confidence Interval
14%
Standard of Care
13%
Allogeneic
13%
Elderly Patients
13%
Autologous Transplantation
13%
Progression-free Survival
13%
Single-center Experience
13%
Randomized Controlled Trial
13%
Maintenance Therapy
13%
Non-relapse Mortality
12%
Bacteremia
12%
Oncology Patients
12%
Chemotherapy
12%
Premature Aging
12%
FLAG-Ida
12%
Second-line Therapy
12%
Hematopoietic Cell Transplant
12%
Adverse Events
11%
Relapsed or Refractory Acute Myeloid Leukemia
10%
Neutropenic Patients
10%
Diffuse Large B-cell Lymphoma (DLBCL)
9%
Tyrosine Kinase Inhibitor
9%
Hypomethylating Agents
9%
Refractory Diffuse Large B-cell Lymphoma
9%
Graft-versus-host Disease Prophylaxis
9%
Bloodstream Infection
8%
Clinical Trials
8%
Hazard Ratio
8%
Multiple Myeloma Patients
8%
Infectious Complications
8%
Multicenter Retrospective Study
8%
Patients with Hematological Malignancies
8%
Antibacterial Prophylaxis
8%
Single Center
7%
Comorbidity
7%
Medicine and Dentistry
Hematopoietic Cell
86%
Cell Transplantation
79%
Acute Myeloid Leukemia
36%
Meta-Analysis
32%
Overall Survival
31%
Systematic Review
28%
Multiple Myeloma
25%
Graft Versus Host Reaction
24%
Venetoclax
24%
Chimeric Antigen Receptor T-Cell Immunotherapy
24%
Infection
23%
Retrospective Study
20%
Large-Cell Lymphoma
18%
Bloodstream Infection
17%
Randomized Controlled Trial
16%
Diseases
15%
Progression Free Survival
14%
Antiinfective Agent
13%
Chronic Graft Versus Host Disease
13%
Diffuse Large B-Cell Lymphoma
13%
Maintenance Therapy
13%
Cohort Analysis
12%
Arm
10%
Elderly Patient
10%
Chimeric Antigen Receptor T-Cell
9%
Non-Relapse Mortality
9%
Neutrophil
9%
Engraftment
9%
Cancer
8%
Comorbidity
8%
Clinical Trial
8%
Hazard Ratio
8%
Hematologic Malignancy
8%
Methotrexate
8%
Platelet
7%
Infusion
7%
Observational Study
7%
Azacitidine
7%
Infectious Complication
7%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Silastic
6%
Thalassemia Major
6%
Gilteritinib
6%
Infective Endocarditis
6%
Cytomegalovirus
6%
Chimeric Antigen Receptor T-Cell Therapy
6%
Ciprofloxacin
6%
Cord Blood Stem Cell Transplantation
6%
Conditioning
6%
Treosulfan
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
33%
Overall Survival
28%
Infection
27%
Randomized Controlled Trial
26%
Venetoclax
24%
Diseases
20%
Multiple Myeloma
19%
Bloodstream Infection
17%
Graft Versus Host Reaction
15%
Retrospective Study
14%
Progression Free Survival
13%
Chemotherapy
13%
Adverse Event
12%
Observational Study
12%
Protein Tyrosine Kinase Inhibitor
10%
Remission
10%
Chronic Graft Versus Host Disease
9%
Clinical Trial
8%
Cohort Study
8%
Methotrexate
8%
Chronic Lymphatic Leukemia
8%
Sorafenib
7%
Hematologic Malignancy
7%
Midostaurin
7%
Antiinfective Agent
7%
Azacitidine
7%
Event Free Survival
7%
Infectious Complication
7%
Diffuse Large B Cell Lymphoma
7%
Neoplasm
6%
Obinutuzumab
6%
Acinetobacter Baumannii
6%
Fluconazole
6%
Streptococcus
6%
Treosulfan
6%
Myocarditis
6%
Large Cell Lymphoma
6%
Cannabidiol
6%
Human Herpesvirus 6
6%
Bendamustine
6%
Thalassemia Major
6%
Ponatinib
6%
Thalassemia
6%
Thalassemia Intermedia
6%
Immunoglobulin Antibody
6%
Folinic Acid
6%
Malignant Neoplasm
6%
Ciprofloxacin
6%
Gilteritinib
6%
Penicillin
6%